Tanox, Inc.
Records under this name other than patents Tanox, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,605,065 | Novel Anti-IL13 Antibodies and Uses Thereof Formerly held Term ended Term ended May 8, 2026 · High confidence | Term ended | Term ended May 8, 2026 | High confidence |
| US 7,674,459 | Treatment of Cancer with Novel ANTI-IL13 Monoclonal Antibodies Formerly held Term ended Term ended Mar 23, 2026 · High confidence | Term ended | Term ended Mar 23, 2026 | High confidence |
| US 8,088,618 | Novel Anti-Il 13 Antibodies and Uses Thereof Formerly held Term ended Term ended Mar 1, 2026 · High confidence | Term ended | Term ended Mar 1, 2026 | High confidence |
| US 9,067,994 | Novel ANTI-IL13 Antibodies and Uses Thereof Formerly held Term ended Term ended Oct 5, 2025 · High confidence | Term ended | Term ended Oct 5, 2025 | High confidence |
| US 8,067,199 | Novel ANTI-IL13 Antibodies and Uses Thereof Term ended Term ended Oct 2, 2025 · High confidence | Term ended | Term ended Oct 2, 2025 | High confidence |
| US 8,734,797 | Novel ANTI-IL13 Antibodies and Uses Thereof Formerly held Term ended Term ended Jan 5, 2025 · High confidence | Term ended | Term ended Jan 5, 2025 | High confidence |
| US 8,734,801 | Novel ANTI-IL13 Antibodies and Uses Thereof Formerly held Term ended Term ended Dec 23, 2024 · High confidence | Term ended | Term ended Dec 23, 2024 | High confidence |
| US 8,252,284 | High affinity, anti-human IgE antibodies Lapsed on the fee record Ended Aug 28, 2024 · From the USPTO record | Lapsed on the fee record | Ended Aug 28, 2024 | From the USPTO record |
| US 9,156,908 | High affinity, anti-human IgE antibodies Term ended Term ended Jun 29, 2024 · From the USPTO record | Term ended | Term ended Jun 29, 2024 | From the USPTO record |
| US 7,531,169 | High affinity anti-human IgE antibodies Term ended Term ended Feb 11, 2024 · From the USPTO record | Term ended | Term ended Feb 11, 2024 | From the USPTO record |